Several studies have indicated that home infusions of biologic agents are safe for selected patients with inflammatory bowel disease. Vedolizumab is a monoclonal antibody directed against the α4β7 integrin and is indicated for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in patients that have had an inadequate response to or demonstrated intolerability to corticosteroids, immunomodulators, or TNF-α inhibitors. Its novel GI-selective target suggests that associated adverse events may differ than those in older biologics. The purpose of this study was to determine the incidence and severity of acute vedolizumab infusion reactions in an alternate site of care. A retrospective chart review was conducted identifying IBD patients who received vedolizumab with one home infusion provider in the home or company Ambulatory Infusion Suite (AIS) between January 2014 and November 2016. Incidence and management of acute IRs were analyzed. IRs that occurred during or within 24 hours of the infusion were considered acute. Reactions were categorized as mild (i.e. transient pruritus, flushing), moderate (i.e. urticaria, dyspnea) or severe (i.e. bronchospasms, angioedema, infusion discontinued, ER visit). A total of 126 infusions administered in 25 patients (16 with ulcerative colitis and 9 with Crohn’s disease) were analyzed. Seventeen patients were female, and the mean age of the patient population was 35.1 years. There was 1 acute IR recorded for a per-infusion reaction rate of 0.8% and a per-patient reaction rate of 4.0%. The reaction consisted of severe nausea and pallor resulting in discontinuance of the infusion. The patient was driven to the ER by a family member. This infusion reaction occurred on the patient’s 22nd maintenance infusion with vedolizumab. Of note, this patient experienced several ulcerative colitis symptom flare-ups in the two-weeks prior to infusion. This patient had tried aminosalicylates and infliximab prior to initiation of vedolizumab and was transitioned due to lack of therapy response and infliximab-related infusion reactions. The reaction did not lead to discontinuation of future vedolizumab infusions. Vedolizumab infusion reactions are rare in an alternate-care setting and may provide a safe alternative to patients intolerant or unresponsive to TNF-alpha inhibitors. Large-scale future studies are needed to identify factors associated with acute infusion reactions to vedolizumab and determine any preventive measures.